Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells
Author Information
Author(s): J. Wang, K.A. Biedermann, C.R. Wolf, J.M. Brown
Primary Institution: Stanford University
Hypothesis
What role do different bioreductive enzymes play in the metabolism of SR 4233 by tumour cells?
Conclusion
SR 4233 is metabolized by tumour cells under hypoxic conditions, primarily through the action of cytochrome P-450.
Supporting Evidence
- Cytochrome P-450 was found to play a major role in the reduction of SR 4233 in both SCCVII and HT 1080 cells.
- NADPH was identified as the most important cofactor in the reduction of SR 4233.
- DT diaphorase was the second most important enzyme in reducing SR 4233, particularly in HT 1080 cells.
- Carbon monoxide inhibited the reduction of SR 4233 by about 60%, suggesting the involvement of cytochrome P-450.
Takeaway
Researchers studied how a cancer drug called SR 4233 is processed by cancer cells, finding that certain enzymes help break it down, especially when there's low oxygen.
Methodology
The study involved assaying the activity of various bioreductive enzymes in two tumour cell lines, SCCVII and HT 1080, under hypoxic conditions.
Limitations
The study does not identify all enzymes involved in the metabolism of SR 4233, leaving some mechanisms unexplored.
Want to read the original?
Access the complete publication on the publisher's website